- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06130579
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
March 19, 2024 updated by: Xiao-Jun Huang, Peking University People's Hospital
Interferon-α for Preventing Relapse in TP53+ Myeloid Malignancy Post Allo-HSCT
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation.
To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
35
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu Wang
- Phone Number: 86-13552647384
- Email: ywyw3172@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Deparment of Hematology, Peking University People's Hospital
-
Contact:
- Xiaojun Huang, doctor
- Phone Number: 8601088326666
- Email: xjrm@medmail.com.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Myelodysplastic syndrome (MDS) diagnosed according to the 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemia (2022ICC) criteria, acute myeloid leukemia (AML) with TP53 mutation (unrestricted remission status), minimal residual disease (MRD) monitored by flow cytometry within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation Negative patients
- Male or female, aged 12-65 years
- Karnofsky score >60, estimated survival time >3 months
No history of severe graft-versus-host disease (GVHD), uncontrolled GVHD, or severe systemic organ dysfunction:
- Absolute neutrophil count (ANC) greater than 0.5×109/L
- Creatinine < 1.5mg/dL
- Cardiac ejection index >55%
- Signed informed consent.
Exclusion Criteria:
- severe cardiac, renal, or liver dysfunction
- combined with other malignant tumors requiring treatment
- inability to understand or adhere to the study protocol due to clinical symptoms of brain dysfunction or severe mental illness
- patients who are unable to complete the necessary treatment plan and follow-up observation
- patients with severe acute anaphylaxis
- clinically uncontrolled severe life-threatening infections
- patients enrolled in other clinical trials
- other reasons considered by the investigator to be inappropriate for clinical trial participants.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IFN-α application in TP53+ myeloid malignancy
|
Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT.
If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation.
The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week.
Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of relapse
Time Frame: 1 year post HSCT
|
Disease relapse was defined as blasts ≥ 5% post transplantation.
|
1 year post HSCT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of non-relapse mortality
Time Frame: 1 year post HSCT.
|
The incidence of non-relapse mortality
|
1 year post HSCT.
|
The incidence of positive minimal residual disease post allo-HSCT
Time Frame: 1 year post HSCT
|
Positive MRD was defined as leukemia-associated immunophenotyping (LAIPs) by flow cytometry.
|
1 year post HSCT
|
The incidence of acute and chronic graft versus host disease (GvHD)
Time Frame: aGvHD within 100 days and cCvHD within 1 year
|
The severity of acute GvHD (aGvHD) and chronic GvHD (cGvHD) was evaluated according to standard criteria.
|
aGvHD within 100 days and cCvHD within 1 year
|
The probability of progression free survival
Time Frame: 1 year post HSCT.
|
Survival without disease progression
|
1 year post HSCT.
|
The probability of overall survival (OS)
Time Frame: 1 year post HSCT.
|
OS was defined as the time from transplantation to death from any cause or to the last follow-up.
|
1 year post HSCT.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
November 8, 2023
First Submitted That Met QC Criteria
November 8, 2023
First Posted (Actual)
November 14, 2023
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IFN-α for preventing relapse
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
Clinical Trials on IFN-Α
-
Beijing 302 HospitalNot yet recruitingHBeAg Positive Chronic Hepatitis BChina
-
The First People's Hospital of ChangzhouNot yet recruiting
-
Fuzhou General HospitalUnknownRenal Cell CarcinomaChina
-
Sohag UniversityNot yet recruiting
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
BioGeneric PharmaXiamen Amoytop Biotech Co., Ltd.UnknownHepatitis C | Self EfficacyEgypt
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
The First Affiliated Hospital of Soochow UniversityRecruitingB-cell Acute Lymphoblastic LeukemiaChina
-
Yao XieUnknownChronic Hepatitis B InfectionChina